Zambon Company SpA is a pharmaceutical and chemical company founded in 1906, with headquarter in Bresso (Milan), Italy. It operates directly in North and South America, Europe and Asia, with over 2,500 employees in 15 Countries and consolidated sales of 555M€ in 2008, 80% of which generated by Zambon Pharmaceuticals SpA. Zambon Pharmaceuticals SpA leading products are Fluimucil (N-Acetylcysteine); Monuril (Fosfomycin tromethamol); Spidifen (Ibuprofen arginine). Main therapeutic areas of interest for Zambon Pharmaceuticals SpA are Respiratory, Women's care and pain relief, with focus on mild-moderate diseases. The Company is developing a portfolio of product ranging from ethical prescription drugs to self-medication products. Zambon Pharmaceuticals SpA has production plants based in EU and China.

Zambon's Pharmaceuticals Corporate Licensing Department is actively looking for in-licensing of products in the Respiratory, Woman's care and Pain relief. Moreover, Zambon Pharmaceuticals SpA is looking for out-licensing core products in territories where the Company is not present with Affiliates. Zambon's current strategy is to develop a portfolio of products ranging from ethical prescription drugs to OTC products that can play a significant role in the target areas. Main medical target currently visited are: GPs, Gynaecologists, ENT, Pediatricians, Pneumologists and Pharmacies, the latter covered by specialized sales lines in all key Countries.